North China Pharmaceutical Company.Ltd (SHA:600812)

Market Cap	8.51B -15.6%
Revenue (ttm)	8.82B -10.8%
Net Income	161.04M -3.2%
EPS	0.09 -2.3%
Shares Out	1.72B
PE Ratio	52.68
Forward PE	n/a
Dividend	0.03 (0.60%)
Ex-Dividend Date	Jul 25, 2025

Volume	10,322,016
Average Volume	13,431,745
Open	4.960
Previous Close	4.960
Day's Range	4.810 - 4.960
52-Week Range	4.820 - 7.460
Beta	0.32
RSI	30.92
Earnings Date	Aug 14, 2026

About SHA:600812

North China Pharmaceutical Company Ltd. operates as a chemical pharmaceutical company in China. It primarily offers anti-infective drugs, comprising APIs, and intermediates and their preparations; biotechnology drugs; cardiovascular and immunomodulators; vitamins health consumer products; and bio-agricultural and veterinary drugs. North China Pharmaceutical Company Ltd. was founded in 1953 and is based in Shijiazhuang, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1992
• Employees: 9,972
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600812

Financial Performance

In 2025, SHA:600812's revenue was 9.24 billion, a decrease of -6.36% compared to the previous year's 9.87 billion. Earnings were 183.06 million, an increase of 44.15%.